Search research articles
Contact Us
Filters
Showing results (231-240 of 293) with videos related to
Page
of 30
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 19, 2009
Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study
Joseph A Sparano, Anatoly N Makhson, Vladimir F Semiglazov, et al.
Cell Reports
|
December 2, 2014
Structure and cancer immunotherapy of the B7 family member B7x
Hyungjun Jeon, Vladimir Vigdorovich, Sarah C Garrett-Thomson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 25, 2018
Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103)
Kathy D Miller, Anne O'Neill, William Gradishar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 30, 2014
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199
Sylvia Adams, Robert J Gray, Sandra Demaria, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 21, 2016
Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure
Bryan P Schneider, Fei Shen, Laura Gardner, et al.
Science Translational Medicine
|
July 7, 2017
Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism
George S Karagiannis, Jessica M Pastoriza, Yarong Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 10, 2017
Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205)
Madhur K Garg, Fengmin Zhao, Joseph A Sparano, et al.
Cancer Discovery
|
May 3, 2020
Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System
Vikas Mehta, Sanjay Goel, Rafi Kabarriti, et al.
Immunity
|
August 1, 2025
Mutations in MLL3 promote breast cancer progression via HIF1α-dependent intratumoral recruitment and differentiation of regulatory T cells
Marie Boutet, Kenta Nishitani, Nicole Couturier, et al.
NPJ Breast Cancer
|
November 9, 2019
If we build it they will come: targeting the immune response to breast cancer
Margaret E Gatti-Mays, Justin M Balko, Sofia R Gameiro, et al.
Page
of 30
Search research articles
Search
Showing results (231-240 of 293) with videos related to
Sort By:
Page
of 30
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 19, 2009
Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study
Joseph A Sparano, Anatoly N Makhson, Vladimir F Semiglazov, et al.
Cell Reports
|
December 2, 2014
Structure and cancer immunotherapy of the B7 family member B7x
Hyungjun Jeon, Vladimir Vigdorovich, Sarah C Garrett-Thomson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 25, 2018
Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103)
Kathy D Miller, Anne O'Neill, William Gradishar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 30, 2014
Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199
Sylvia Adams, Robert J Gray, Sandra Demaria, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 21, 2016
Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure
Bryan P Schneider, Fei Shen, Laura Gardner, et al.
Science Translational Medicine
|
July 7, 2017
Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism
George S Karagiannis, Jessica M Pastoriza, Yarong Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 10, 2017
Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205)
Madhur K Garg, Fengmin Zhao, Joseph A Sparano, et al.
Cancer Discovery
|
May 3, 2020
Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System
Vikas Mehta, Sanjay Goel, Rafi Kabarriti, et al.
Immunity
|
August 1, 2025
Mutations in MLL3 promote breast cancer progression via HIF1α-dependent intratumoral recruitment and differentiation of regulatory T cells
Marie Boutet, Kenta Nishitani, Nicole Couturier, et al.
NPJ Breast Cancer
|
November 9, 2019
If we build it they will come: targeting the immune response to breast cancer
Margaret E Gatti-Mays, Justin M Balko, Sofia R Gameiro, et al.
Page
of 30